Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data

To investigate the cost-effectiveness of abatacept (ABA) as first-line (1L) therapy in Japanese rheumatoid arthritis (RA) patients using data from the Institute of Rheumatology, Rheumatoid Arthritis database. A decision-analytic model was used to estimate the cost per American College of Rheumatolog...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2022-11, Vol.17 (11), p.e0277566
Hauptverfasser:	Tanaka, Eiichi, Inoue, Eisuke, Shoji, Ayako, Nilsson, Jonas, Papagiannopoulos, Christos, Dhanda, Devender, Yoshizawa, Yuri, Abe, Mai, Saka, Kumiko, Sugano, Eri, Sugitani, Naohiro, Ochiai, Moeko, Yamaguchi, Rei, Ikari, Katsunori, Yamanaka, Hisashi, Harigai, Masayoshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Abatacept - therapeutic use Aged Antirheumatic Agents - adverse effects Arthritis Arthritis, Rheumatoid Biology and Life Sciences Clinical medicine Cohort analysis Cost analysis Costs Data centers Decision analysis Diabetes Disease Effectiveness Health care Humans Japan Medicine and Health Sciences Parameter sensitivity Parameter uncertainty Patients People and Places Pneumonia Remission Remission (Medicine) Research and Analysis Methods Rheumatoid arthritis Rheumatology Social Sciences Subgroups Treatment Outcome Tuberculosis Tumor necrosis factor Tumor Necrosis Factor Inhibitors Tumor necrosis factor-TNF Tumors United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!